168 related articles for article (PubMed ID: 28101885)
1. What is the true in vitro potency of oxytetracycline for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida?
Dorey L; Hobson S; Lees P
J Vet Pharmacol Ther; 2017 Oct; 40(5):517-529. PubMed ID: 28101885
[TBL] [Abstract][Full Text] [Related]
2. Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens.
Dorey L; Lees P
BMC Vet Res; 2017 Jun; 13(1):192. PubMed ID: 28645327
[TBL] [Abstract][Full Text] [Related]
3. Potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida: Comparison of growth media.
Dorey L; Hobson S; Lees P
Res Vet Sci; 2017 Apr; 111():43-48. PubMed ID: 27940285
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing the potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Hobson S; Lees P
Res Vet Sci; 2017 Apr; 111():93-98. PubMed ID: 28113129
[TBL] [Abstract][Full Text] [Related]
5. Activity of florfenicol for Actinobacillus pleuropneumoniae and Pasteurella multocida using standardised versus non-standardised methodology.
Dorey L; Hobson S; Lees P
Vet J; 2016 Dec; 218():65-70. PubMed ID: 27938711
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of doxycycline and oxytetracycline against porcine respiratory pathogens.
Bousquet E; Morvan H; Aitken I; Morgan JH
Vet Rec; 1997 Jul; 141(2):37-40. PubMed ID: 9253829
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Pelligand L; Cheng Z; Lees P
J Vet Pharmacol Ther; 2017 Oct; 40(5):505-516. PubMed ID: 28090673
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial activity of tilmicosin against Pasteurella multocida and Actinobacillus pleuropneumoniae isolated from pneumonic lesions in swine.
Inamoto T; Kikuchi K; Iijima H; Kawashima Y; Nakai Y; Ogimoto K
J Vet Med Sci; 1994 Oct; 56(5):917-21. PubMed ID: 7865594
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial resistance genes in Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida isolated from Australian pigs.
Dayao D; Gibson JS; Blackall PJ; Turni C
Aust Vet J; 2016 Jul; 94(7):227-31. PubMed ID: 27349882
[TBL] [Abstract][Full Text] [Related]
10. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.
Dorey L; Pelligand L; Lees P
BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Pelligand L; Cheng Z; Lees P
PLoS One; 2017; 12(5):e0177568. PubMed ID: 28552968
[TBL] [Abstract][Full Text] [Related]
12. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Blondeau JM; Fitch SD
PLoS One; 2019; 14(1):e0210154. PubMed ID: 30629633
[TBL] [Abstract][Full Text] [Related]
13. Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine.
Moore GM; Basson RP; Tonkinson LV
Am J Vet Res; 1996 Feb; 57(2):224-8. PubMed ID: 8633813
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida and Salmonella choleraesuis isolates from pigs.
Raemdonck DL; Tanner AC; Tolling ST; Michener SL
Vet Rec; 1994 Jan; 134(1):5-7. PubMed ID: 8128570
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.
Lees P; Potter T; Pelligand L; Toutain PL
J Vet Pharmacol Ther; 2018 Feb; 41(1):28-38. PubMed ID: 28736817
[TBL] [Abstract][Full Text] [Related]
16. Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella multocida and Actinobacillus pleuropneumoniae associated with porcine respiratory disease.
Shryock TR; Staples JM; DeRosa DC
J Vet Diagn Invest; 2002 Sep; 14(5):389-95. PubMed ID: 12296390
[TBL] [Abstract][Full Text] [Related]
17. In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs.
Blackall PJ; Asakawa T; Graydon RJ; White M; Adamson M; Wade LK; Lowe LB
Aust Vet J; 1995 Jan; 72(1):35-6. PubMed ID: 8787526
[No Abstract] [Full Text] [Related]
18. Comparison of standardised versus non-standardised methods for testing the in vitro potency of oxytetracycline against Mannheimia haemolytica and Pasteurella multocida.
Lees P; Illambas J; Pelligand L; Toutain PL
Vet J; 2016 Dec; 218():60-64. PubMed ID: 27938710
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pigs experimentally infected with Mycoplasma hyopneumoniae, Pasteurella multocida, and Actinobacillus pleuropneumoniae with various antibiotics.
Stipkovits L; Miller D; Glavits R; Fodor L; Burch D
Can J Vet Res; 2001 Oct; 65(4):213-22. PubMed ID: 11768127
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Actinobacillus pleuropneumoniae, Actinobacillus suis, Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis in representative Ontario swine herds.
MacInnes JI; Gottschalk M; Lone AG; Metcalf DS; Ojha S; Rosendal T; Watson SB; Friendship RM
Can J Vet Res; 2008 Apr; 72(3):242-8. PubMed ID: 18505187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
